Proportion of treatment effect explained by on-study biomarkers
cardiovascular death, kidney disease
In exploratory analyses, on-study levels of uACR, SBP, DBP and HbA1c
explained 41% (95% CI: 23–77%) of the treatment effect on the primary
composite of kidney disease progression or cardiovascular death (an attenuation
of the hazard ratio from 0.73 [0.63–0.83] to 0.83 [0.72–0.95], and
67% reduction in 